ReviewEye (London, England)2017
Uveal melanoma: relatively rare but deadly cancer.
Review in Eye (London, England), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 382 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
382 citing papers in PubMed, 3 syntheses or guidelines pooled it, 638 citations in OpenAlex.
- GWAS meta-analysis provides new insights into uveal melanoma risk.British journal of cancer · 2026Pooled it
- Pooled it
- A large-scale genome-wide association meta-analysis for nevus count provides direct insights into the genetics of melanoma.Nature communications · 2026Pooled it
- Clinical Classification of Radiation Maculopathy as a Predictor of Functional Response to Intravitreal Dexamethasone Implant.Journal of clinical medicine · 2026Article
- Choroidal melanoma edge recurrence 13 years after IAmerican journal of ophthalmology case reports · 2026Article
- Deep Learning Classification of Uveal Melanoma and Metastatic Carcinoma on Cytology Specimens: A Single-Center Experience.Investigative ophthalmology & visual science · 2026Article
- Unilateral Glaucoma as a Clinical Indicator of Iris and Ciliary Body Melanoma.Ocular oncology and pathology · 2026Article
- Gene Therapy Strategies for Uveal Melanoma: Adeno-associated Virus Delivery Challenges and Translational Opportunities.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026Review
- A Possible Link Between Cutaneous Melanoma and Uveal Melanoma: A Multicenter Retrospective Cohort Study.Cancers · 2026Article
- Potential of Nanoparticle-Based Phototherapies for Future Treatment of Uveal Melanoma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- GNAQ Induces Melanomagenesis in Mitfa-Independent Melanocyte Progenitors in a Zebrafish Model of Uveal Melanoma.Cancer research · 2026Article
- Physical Activity Is Associated with Higher Retinal Microvascular Density in Uveal Melanoma and Nevus.Cancers · 2026Article
- Pointmaps to Practice: 3D Multi-view Ocular Lesion Mapping.Journal of imaging informatics in medicine · 2026Article
- Imaging-based machine learning for the diagnosis and prognosis of uveal melanoma: a systematic review and meta analysis.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Review
- Does the ERBB/EGF Signaling Network Serve as a Nexus for Oncogenic Signals in Uveal Melanoma?Biomolecules · 2026Review
- Incidentally Detected Large Choroidal Melanoma in a 27-Year-Old Asymptomatic Woman: A Case Report.Cureus · 2026Article
- Hepatic metastasis surveillance in uveal melanoma: a retrospective cohort study from a UK tertiary centre (2006-2022).British journal of cancer · 2026Article
- Diabetes mellitus is associated with earlier detection of posterior uveal melanoma.European journal of ophthalmology · 2026Article
- National Coordinated Care and Translational Research Program for Uveal Melanoma Pilot: Infrastructure, Biobanking, and Challenges in Liquid Biopsy Implementation in a Latin American Country.Ocular oncology and pathology · 2026Article
- Recent advances in the molecular genetic mechanisms and immune microenvironment of uveal melanoma.Melanoma research · 2026Review
322 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although it is a relatively rare disease, primarily found in the Caucasian population, uveal melanoma is the most common primary intraocular tumor in adults with a mean age-adjusted incidence of 5.1 cases per million per year. Tumors are located either in iris (4%), ciliary body (6%), or choroid (90%). The host susceptibility factors for uveal melanoma include fair skin, light eye color, inability to tan, ocular or oculodermal melanocytosis, cutaneous or iris or choroidal nevus, and BRCA1-associated protein 1 mutation. Currently, the most widely used first-line treatment options for this malignancy are resection, radiation therapy, and enucleation. There are two main types of radiation therapy: plaque brachytherapy (iodine-125, ruthenium-106, or palladium-103, or cobalt-60) and teletherapy (proton beam, helium ion, or stereotactic radiosurgery using cyber knife, gamma knife, or linear accelerator). The alternative to radiation is enucleation. Although these therapies achieve satisfactory local disease control, long-term survival rate for patients with uveal melanoma remains guarded, with risk for liver metastasis. There have been advances in early diagnosis over the past few years, and with the hope survival rates could improve as smaller tumors are treated. As in many other cancer indications, both early detection and early treatment could be critical for a positive long-term survival outcome in uveal melanoma. These observations call attention to an unmet medical need for the early treatment of small melanocytic lesions or small melanomas in the eye to achieve local disease control and vision preservation with the possibility to prevent metastases and improve overall patient survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.